SSG-mediated SHP-1 inhibition increases Th17 development. (A) Relative Th17 T-cell generation in IL-6 dose-response assay comparing SSG-treated and -untreated +/+ T cells (maximum % Th17 cells: 46% untreated, 47% SSG treated). EC₅₀: untreated +/+ cells 1.0 ng/mL IL-6 (n = 2) and SSG-treated cells 0.25 ng/mL IL-6 (n = 2; P = .04). (B) IL-17A/F expression of CD4⁺ T cells from +/+, me/+, and me/me BALB/c DO11.10 mice that were cultured with or without SSG under Th17-inducing conditions with the indicated concentrations of IL-6. Profiles show CD4⁺-gated population. Data are representative of 2 independent experiments with multiple mice for each genotype.